Teva Pharmaceutical Industries (TEVA) P/E ratio
Teva Pharmaceutical Industries (TEVA) trades at 99.1× its earnings per share over the last twelve months. At the end of fiscal 2025 (December 31, 2025) its P/E ratio was 25.8×. Today's figure is 284.3% above the fiscal 2025 year-end. Figures as of 18 Nov 2026, 10:51 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/E ratio today
- 99.1×
- P/E ratio, fiscal 2025
- 25.8×
- Highest on record
- 56.8×fiscal 2008
- Lowest on record
- 13.1×fiscal 2011
- Fiscal years on record
- 112007–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Teva Pharmaceutical Industries P/E ratio, in more detail
Across the 11 fiscal year-ends on record (2007–2025), the highest was 56.8× in fiscal 2008 and the lowest 13.1× in fiscal 2011. Today's P/E ratio is above every one of the 11 fiscal year-ends on record; their median is 21.1×.
P/E ratio at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
Teva Pharmaceutical Industries P/E ratio, year by year
| Fiscal year | P/E ratio | Change | Year ended | Share price at year-end | Diluted EPS |
|---|---|---|---|---|---|
| Today | 99.1× | — | $42.62 | — | |
| 2025 | 25.8× | — | $31.21 | $1.21 | |
| 2024 | — | — | $22.04 | -$1.45 | |
| 2023 | — | — | $10.44 | -$0.50 | |
| 2022 | — | — | $9.12 | -$2.12 | |
| 2021 | 21.1× | — | $8.01 | $0.38 | |
| 2020 | — | — | $9.65 | -$3.64 | |
| 2019 | — | — | $9.80 | -$0.91 | |
| 2018 | — | — | $15.42 | -$2.35 | |
| 2017 | — | — | $18.95 | -$16.26 | |
| 2016 | — | — | $36.25 | $0.07 | |
| 2015 | 36.1× | 123.3% up | $65.64 | $1.82 | |
| 2014 | 16.2× | 39.9% down | $57.51 | $3.56 | |
| 2013 | 26.9× | 62.1% up | $40.08 | $1.49 | |
| 2012 | 16.6× | 27.1% up | $37.34 | $2.25 | |
| 2011 | 13.1× | 8.0% down | $40.36 | $3.09 | |
| 2010 | 14.2× | 43.6% down | $52.13 | $3.67 | |
| 2009 | 25.2× | 55.6% down | $56.18 | $2.23 | |
| 2008 | 56.8× | 188.2% up | $42.57 | $0.75 | |
| 2007 | 19.7× | — | $46.48 | $2.36 |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.
How to read it
It is the number of years of current profit the price pays for — a high figure means investors expect growth, and it is best judged against the company's own history.
P/E ratio at health care companies of similar size
| Company | P/E ratio |
|---|---|
| Medline MDLN | 85.6× |
| Humana HUM | 43.3× |
| Agilent Technologies A | 34.0× |
| Teva Pharmaceutical Industries TEVA | 99.1× |
| BeOne Medicines ONC | 53.0× |
| Waters WAT | 188.2× |
Price over the last twelve months' earnings per share, as the market data feed reports it.
Teva Pharmaceutical Industries, figure by figure
- Teva Pharmaceutical Industries market cap
- Teva Pharmaceutical Industries revenue
- Teva Pharmaceutical Industries earnings
- Teva Pharmaceutical Industries earnings per share (EPS)
- Teva Pharmaceutical Industries P/S ratio
- Teva Pharmaceutical Industries P/B ratio
- Teva Pharmaceutical Industries free cash flow
- Teva Pharmaceutical Industries operating margin
- Teva Pharmaceutical Industries dividend
- Teva Pharmaceutical Industries shares outstanding
- Teva Pharmaceutical Industries total debt
- Teva Pharmaceutical Industries cash on hand
- Teva Pharmaceutical Industries total assets
- Teva Pharmaceutical Industries return on equity (ROE)
- Teva Pharmaceutical Industries return on invested capital (ROIC)
Teva Pharmaceutical Industries (TEVA) overview: price, valuation and scorecardAll health care companies by market value
Teva Pharmaceutical Industries P/E ratio: questions and answers
What is Teva Pharmaceutical Industries's P/E ratio?
Teva Pharmaceutical Industries (TEVA) trades at 99.1× its earnings per share over the last twelve months. At the end of fiscal 2025 (December 31, 2025) its P/E ratio was 25.8×.
Is Teva Pharmaceutical Industries's P/E ratio high or low compared with its own history?
Today's P/E ratio is above every one of the 11 fiscal year-ends on record; their median is 21.1×.
What are the highest and lowest P/E ratio figures on record for Teva Pharmaceutical Industries?
Across the 11 fiscal year-ends on record (2007–2025), the highest was 56.8× in fiscal 2008 and the lowest 13.1× in fiscal 2011.
How is Teva Pharmaceutical Industries's P/E ratio calculated?
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E. For Teva Pharmaceutical Industries it is on record here for 11 fiscal years, 2007 to 2025.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/E ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Teva Pharmaceutical Industries (TEVA) P/E ratio”, data as of 18 November 2026. https://funkfolio.com/stock/TEVA/pe-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.